% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Fuchs:182439,
      author       = {J. Fuchs and A. Murtha-Lemekhova and J. Pfeiffenberger and
                      A. Fichtner and P. Günther and N. Halama$^*$ and P. Mayer
                      and D. Hornuss and R. Klotz and P. Probst and K. Hoffmann},
      collaboration = {R. Initiative},
      title        = {{G}enerating evidence for diagnosis and therapy of {R}ar{E}
                      {LIVE}r disease: the {RELIVE} {I}nitiative for systematic
                      reviews and meta-analyses.},
      journal      = {Systematic Reviews},
      volume       = {11},
      number       = {1},
      issn         = {2046-4053},
      address      = {London},
      publisher    = {Biomed Central},
      reportid     = {DKFZ-2022-02648},
      pages        = {235},
      year         = {2022},
      note         = {Commentary},
      abstract     = {Rare liver lesions and diseases have seldomly aroused major
                      interest of researchers. For most guidelines, presumably
                      similar clinical conditions are pooled without detailed
                      investigations of singularities that they present.A
                      multidisciplinary project aiming to establish evidence-based
                      therapies for rare liver diseases has been founded. A series
                      of systematic reviews and meta-analyses will be the starting
                      point for a structured development of guidelines for rare
                      conditions of the liver affecting pediatric and adult
                      populations. The novel approach will be focusing on case
                      reports and small patient series with distinct rare liver
                      diseases without pooling several presumably acceptably
                      similar conditions. Thus, a vital resource of information
                      will be utilized, which has been largely neglected
                      hitherto.Highly specific recommendations based on highest
                      available evidence will therefore be developed for specific
                      conditions, advancing the individualized medicine approach
                      for the afflicted patients.},
      subtyp        = {Review Article},
      keywords     = {Evidence-based medicine (Other) / Meta-analysis (Other) /
                      RELIVE (Other) / Rare liver disease (Other) / Rare liver
                      tumors (Other) / Systematic reviews (Other)},
      cin          = {D240},
      ddc          = {610},
      cid          = {I:(DE-He78)D240-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36329524},
      doi          = {10.1186/s13643-022-02105-0},
      url          = {https://inrepo02.dkfz.de/record/182439},
}